Bavunalimab

Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer[1].

Product Specifications

CAS Number

[2329669-78-3]

Product Name Alternative

Anti-Human CTLA4xLAG3; XmAb-22841

UNSPSC

12352203

Target

LAG-3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bavunalimab.html

Purity

99.408

Solubility

H2O

Smiles

[Bavunalimab]

Molecular Weight

(125.327 kDa)

References & Citations

[1]Perez-Santos M, et, al. Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents. Expert Opin Drug Discov. 2022 Nov 24;1-15.